- Joined
- Feb 25, 2011
- Messages
- 2,256
For those who have researched or used the 2 below. Any thoughts? Any issues with the body pushing out the glucose as far as training, pumps, etc?
First, the Food and Drug Administration approved the SGLT2 inhibitor Farxiga® (dapagliflozin), followed by Jardiance® (empagliflozin), to reduce the risk of death and hospitalization in people who have heart failure with reduced ejection fraction.
Farxiga
Treats symptomatic chronic heart failure
Treats chronic kidney disease
Can lower blood sugar levels in people with Type 2 diabetes
FDA-approved heart failure benefit: reduces risk of hospitalization from heart failure
Evidence of kidney benefit
Jardiance
Treats symptomatic chronic heart failure
Can lower blood sugar levels in people with Type 2 diabetes
FDA-approved cardiovascular benefit: reduces risk of cardiovascular death
Evidence for heart failure benefit: reduces risk of hospitalization from heart failure
Evidence of kidney benefit
First, the Food and Drug Administration approved the SGLT2 inhibitor Farxiga® (dapagliflozin), followed by Jardiance® (empagliflozin), to reduce the risk of death and hospitalization in people who have heart failure with reduced ejection fraction.
Farxiga
Treats symptomatic chronic heart failure
Treats chronic kidney disease
Can lower blood sugar levels in people with Type 2 diabetes
FDA-approved heart failure benefit: reduces risk of hospitalization from heart failure
Evidence of kidney benefit
Jardiance
Treats symptomatic chronic heart failure
Can lower blood sugar levels in people with Type 2 diabetes
FDA-approved cardiovascular benefit: reduces risk of cardiovascular death
Evidence for heart failure benefit: reduces risk of hospitalization from heart failure
Evidence of kidney benefit